Depreciation, Depletion and Amortization of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. from 27 Mar 2010 to 27 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. quarterly and annual Depreciation, Depletion and Amortization in USD history and change rate from 27 Mar 2010 to 27 Sep 2025.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Depreciation, Depletion and Amortization for the quarter ending 27 Sep 2025 was $85,164,000, a 3.4% decline year-over-year.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Depreciation, Depletion and Amortization for the twelve months ending 27 Sep 2025 was $427,139,000, a 26% increase year-over-year.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. annual Depreciation, Depletion and Amortization for 2024 was $361,741,000, a 15% increase from 2023.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. annual Depreciation, Depletion and Amortization for 2023 was $314,124,000, a 3.4% increase from 2022.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. annual Depreciation, Depletion and Amortization for 2022 was $303,870,000, a 14% increase from 2021.
Source SEC data
View on sec.gov
Depreciation, Depletion and Amortization, Trailing 12 Months (USD)
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Change (%)
Depreciation, Depletion and Amortization, Annual (USD)
Depreciation, Depletion and Amortization, YoY Annual Change (%)

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Quarterly Depreciation, Depletion and Amortization (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $427,139,000 $85,164,000 -$3,034,000 -3.4% 29 Jun 2025 27 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $430,173,000 $119,507,000 +$33,425,000 +39% 30 Mar 2025 28 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $396,748,000 $120,364,000 +$35,007,000 +41% 29 Dec 2024 29 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $361,741,000 $102,104,000 +$21,590,000 +27% 29 Sep 2024 28 Dec 2024 10-K 19 Feb 2025 2024 FY
Q3 2024 $340,151,000 $88,198,000 +$9,328,000 +12% 30 Jun 2024 28 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $330,823,000 $86,082,000 +$8,411,000 +11% 31 Mar 2024 29 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $322,412,000 $85,357,000 +$8,288,000 +11% 31 Dec 2023 30 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $314,124,000 $80,514,000 +$2,969,000 +3.8% 01 Oct 2023 30 Dec 2023 10-K 19 Feb 2025 2024 FY
Q3 2023 $311,155,000 $78,870,000 +$4,265,000 +5.7% 02 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $306,890,000 $77,671,000 +$1,250,000 +1.6% 02 Apr 2023 01 Jul 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $305,640,000 $77,069,000 +$1,770,000 +2.4% 01 Jan 2023 01 Apr 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $303,870,000 $77,545,000 +$10,304,000 +15% 25 Sep 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
Q3 2022 $293,566,000 $74,605,000 +$5,919,000 +8.6% 26 Jun 2022 24 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $287,647,000 $76,421,000 +$8,316,000 +12% 27 Mar 2022 25 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $279,331,000 $75,299,000 +$13,791,000 +22% 26 Dec 2021 26 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $265,540,000 $67,241,000 +$6,365,000 +10% 26 Sep 2021 25 Dec 2021 10-K 14 Feb 2024 2023 FY
Q3 2021 $259,175,000 $68,686,000 +$9,106,000 +15% 27 Jun 2021 25 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $250,069,000 $68,105,000 +$10,897,000 +19% 28 Mar 2021 26 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $239,172,000 $61,508,000 +$4,248,000 +7.4% 27 Dec 2020 27 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $234,924,000 $60,876,000 +$9,043,000 +17% 27 Sep 2020 26 Dec 2020 10-K 22 Feb 2023 2022 FY
Q3 2020 $225,881,000 $59,580,000 +$7,822,000 +15% 28 Jun 2020 26 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $218,059,000 $57,208,000 +$8,062,000 +16% 29 Mar 2020 27 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $209,997,000 $57,260,000 +$11,902,000 +26% 29 Dec 2019 28 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $198,095,000 $51,833,000 +$10,252,000 +25% 29 Sep 2019 28 Dec 2019 10-K 16 Feb 2022 2021 FY
Q3 2019 $187,843,000 $51,758,000 +$8,166,000 +19% 30 Jun 2019 28 Sep 2019 10-Q 29 Oct 2020 2020 Q3
Q2 2019 $179,677,000 $49,146,000 +$5,750,000 +13% 31 Mar 2019 29 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $173,927,000 $45,358,000 +$12,148,000 +37% 30 Dec 2018 30 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $161,779,000 $41,581,000 +$8,097,000 +24% 30 Sep 2018 29 Dec 2018 10-K 17 Feb 2021 2020 FY
Q3 2018 $153,682,000 $43,592,000 +$10,127,000 +30% 01 Jul 2018 29 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $143,555,000 $43,396,000 +$11,597,000 +36% 01 Apr 2018 30 Jun 2018 10-Q 31 Jul 2019 2019 Q2
Q1 2018 $131,958,000 $33,210,000 +$799,000 +2.5% 31 Dec 2017 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $131,159,000 $33,484,000 -$2,058,000 -5.8% 01 Oct 2017 30 Dec 2017 10-K 11 Feb 2020 2019 FY
Q3 2017 $133,217,000 $33,465,000 -$643,000 -1.9% 02 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $133,860,000 $31,799,000 -$554,000 -1.7% 02 Apr 2017 01 Jul 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $134,414,000 $32,411,000 +$7,756,000 +31% 01 Jan 2017 01 Apr 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $126,658,000 $35,542,000 +$9,991,000 +39% 25 Sep 2016 31 Dec 2016 10-K 13 Feb 2019 2018 FY
Q3 2016 $116,667,000 $34,108,000 +$10,294,000 +43% 26 Jun 2016 24 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $106,373,000 $32,353,000 +$9,205,000 +40% 27 Mar 2016 25 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $97,168,000 $24,655,000 +$2,287,000 +10% 27 Dec 2015 26 Mar 2016 10-Q 10 May 2017 2017 Q1
Q4 2015 $94,881,000 $25,551,000 -$474,000 -1.8% 27 Sep 2015 26 Dec 2015 10-K 13 Feb 2018 2017 FY
Q3 2015 $95,355,000 $23,814,000 -$2,254,000 -8.6% 28 Jun 2015 26 Sep 2015 10-Q 02 Nov 2016 2016 Q3
Q2 2015 $97,609,000 $23,148,000 -$1,154,000 -4.7% 29 Mar 2015 27 Jun 2015 10-Q 03 Aug 2016 2016 Q2
Q1 2015 $98,763,000 $22,368,000 +$2,318,000 +12% 28 Dec 2014 28 Mar 2015 10-Q 04 May 2016 2016 Q1
Q4 2014 $96,445,000 $26,025,000 28 Sep 2014 27 Dec 2014 10-K 14 Feb 2017 2016 FY
Q3 2014 $26,068,000 29 Jun 2014 27 Sep 2014 10-Q 04 Nov 2015 2015 Q3
Q2 2014 $24,302,000 30 Mar 2014 28 Jun 2014 10-Q 30 Jul 2015 2015 Q2
Q1 2014 $20,050,000 +$40,000 +0.2% 29 Dec 2013 29 Mar 2014 10-Q 30 Apr 2015 2015 Q1
Q1 2013 $20,010,000 +$8,000 +0.04% 30 Dec 2012 30 Mar 2013 10-Q 30 Apr 2014 2014 Q1
Q1 2012 $20,002,000 -$1,263,000 -5.9% 01 Jan 2012 31 Mar 2012 10-Q 08 May 2013 2013 Q1
Q1 2011 $21,265,000 -$2,315,000 -9.8% 26 Dec 2010 26 Mar 2011 10-Q 04 May 2012 2012 Q1
Q1 2010 $23,580,000 27 Dec 2009 27 Mar 2010 10-Q 04 May 2011 2011 Q1

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Annual Depreciation, Depletion and Amortization (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $361,741,000 +$47,617,000 +15% 31 Dec 2023 28 Dec 2024 10-K 19 Feb 2025 2024 FY
2023 $314,124,000 +$10,254,000 +3.4% 01 Jan 2023 30 Dec 2023 10-K 19 Feb 2025 2024 FY
2022 $303,870,000 +$38,330,000 +14% 26 Dec 2021 31 Dec 2022 10-K 19 Feb 2025 2024 FY
2021 $265,540,000 +$30,616,000 +13% 27 Dec 2020 25 Dec 2021 10-K 14 Feb 2024 2023 FY
2020 $234,924,000 +$36,829,000 +19% 29 Dec 2019 26 Dec 2020 10-K 22 Feb 2023 2022 FY
2019 $198,095,000 +$36,316,000 +22% 30 Dec 2018 28 Dec 2019 10-K 16 Feb 2022 2021 FY
2018 $161,779,000 +$30,620,000 +23% 31 Dec 2017 29 Dec 2018 10-K 17 Feb 2021 2020 FY
2017 $131,159,000 +$4,501,000 +3.6% 01 Jan 2017 30 Dec 2017 10-K 11 Feb 2020 2019 FY
2016 $126,658,000 +$31,777,000 +33% 27 Dec 2015 31 Dec 2016 10-K 13 Feb 2019 2018 FY
2015 $94,881,000 -$1,564,000 -1.6% 28 Dec 2014 26 Dec 2015 10-K 13 Feb 2018 2017 FY
2014 $96,445,000 -$191,000 -0.2% 29 Dec 2013 27 Dec 2014 10-K 14 Feb 2017 2016 FY
2013 $96,636,000 +$15,361,000 +19% 30 Dec 2012 28 Dec 2013 10-K 12 Feb 2016 2015 FY
2012 $81,275,000 -$3,955,000 -4.6% 01 Jan 2012 29 Dec 2012 10-K 17 Feb 2015 2014 FY
2011 $85,230,000 -$8,419,000 -9% 26 Dec 2010 31 Dec 2011 10-K 25 Feb 2014 2013 FY
2010 $93,649,000 27 Dec 2009 25 Dec 2010 10-K 27 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.